Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s Pharmaceutical TechnologyThe real-world data study tracked Parkinson's disease patients for 12 months during treatment with AbbVie's VyalevNeuroscienceRead full story pharminent July 1, 2026 (Last updated: July 1, 2026) Pharmaceutical Technology The real-world data study tracked Parkinson’s disease patients for 12 months during treatment with AbbVie’s Vyalev Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly’s Jaypirca Wins CHMP Opinion for CLL Across All LinesNext: Ipsen Acquires Memo Therapeutics for Up to €700M in Second Deal in Three Days Related Stories Clinical Data Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes pharminent June 30, 2026 Clinical Data BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit pharminent June 29, 2026 Clinical Data Pfizer drug acquired in Seagen deal disappoints in lung cancer study pharminent June 23, 2026
